Japan Cancels One Third Flu Vaccines Order With GSK
This article was originally published in PharmAsia News
Japan's Minister of Health, Labor and Welfare Akira Nagatsuma March 26 announced that the government has reached an agreement with GlaxoSmithKline to cancel the order of 23.68 million doses of H1N1 flu vaccines
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.